Curt A. Ries, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Curt A. Ries, MD

Professor, Department of Medicine (Hematology/Oncology), UCSF

Phone: (415) 353-2421 (appts)
Box 0324, UCSF
San Francisco, CA 94143-0324

View on UCSF Profiles

Education

Johns Hopkins University, 1957-1960, Biological Sciences
University of Rochester School of Medicine, M.D., 1960-1964, Medicine


Professional Experience

  • 1964-1965
    Intern in Medicine, Strong Memorial Hospital, Rochester, NY
  • 1965-1966
    Assistant Resident in Medicine, Strong Memorial Hospital, Rochester, NY
  • 1968-1969
    Resident in Medicine (II), University of California Hospitals, San Francisco, CA
  • 1969-1970
    Chief Resident in Medicine, University of California Hospitals (San Francisco General Hospital), San Francisco, CA
  • 1970-1972
    Fellow in Hematology, University of California, San Francisco, CA
  • 1972-1976
    Assistant Clinical Professor of Medicine, Laboratory Medicine, and Radiology (Nuclear Medicine), University of California, San Francisco, CA
  • 1972-1974
    Chief, Hematology Clinic, University of California Medical Center, San Francisco, CA
  • 1974-1980
    Director, Hematology & Oncology Clinics, University of California Medical Center, San Francisco, CA
  • 1976-1983
    Associate Clinical Professor of Medicine and Laboratory Medicine, University of California, San Francisco, CA
  • 1989-1991
    Director, Adult Bone Marrow Transplant Program, University of California Medical Center, San Francisco, CA
  • 1975-2002
    Director, Outpatient Transfusion Service, University of California Medical Center, San Francisco, CA
  • 1980-2002
    Director, Hematology/Oncology Faculty Practice, University of California Medical Center, San Francisco, CA
  • 1983-2003
    Clinical Professor of Medicine, University of California, San Francisco, CA
  • 2003-present
    Clinical Professor of Medicine Emeritus, University of California, San Francisco, CA

Selected Publications

  1. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant. 2006 Mar; 12(3):316-24.
    View on PubMed
  2. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. Cancer Chemother Pharmacol. 2004 Jun; 53(6):468-74.
    View on PubMed
  3. High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant. 2003 Oct; 9(10):643-8.
    View on PubMed
  4. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002 May 15; 20(10):2464-71.
    View on PubMed
  5. Autologous stem cell transplantation for advanced acute myeloid leukemia. Bone Marrow Transplant. 2002 Feb; 29(4):297-301.
    View on PubMed
  6. High-dose chemotherapy (CTM) for breast cancer. Bone Marrow Transplant. 2000 Aug; 26(3):257-68.
    View on PubMed
  7. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transplant. 2000; 6(1):50-7.
    View on PubMed
  8. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res. 1999 May; 5(5):1115-24.
    View on PubMed
  9. Lung transplantation for pulmonary amyloidosis: a case report. J Heart Lung Transplant. 1998 Nov; 17(11):1129-32.
    View on PubMed
  10. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplant. 1998 Nov; 22(9):865-72.
    View on PubMed
  11. A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia. 1997 Apr; 11(4):485-9.
    View on PubMed
  12. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol. 1997 Feb; 15(2):833-9.
    View on PubMed
  13. The role of endoscopic evaluation in patients with suspected intestinal graft-versus-host disease after allogeneic bone-marrow transplantation. Endoscopy. 1996 Oct; 28(8):680-5.
    View on PubMed
  14. Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia. Bone Marrow Transplant. 1996 Jan; 17(1):93-9.
    View on PubMed
  15. Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia. Leukemia. 1994 Apr; 8(4):535-41.
    View on PubMed
  16. High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma and multiple myeloma. Prog Clin Biol Res. 1994; 389:505-11.
    View on PubMed
  17. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update. Semin Oncol. 1993 Aug; 20(4 Suppl 4):40-8; quiz 49.
    View on PubMed
  18. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood. 1993 Jan 15; 81(2):311-8.
    View on PubMed
  19. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood. 1992 Oct 15; 80(8):1890-5.
    View on PubMed
  20. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood. 1991 Dec 1; 78(11):2814-22.
    View on PubMed

Go to UCSF Profiles, powered by CTSI